Search results
Psychedelic therapy data ‘speaks for itself,’ VA official says
Military Times via Yahoo News· 7 hours agoThe VA’s top health official said the agency is prepared to spend “at least in the millions” on...
Cream cheese recalled nationwide over possible salmonella risk
The Independent via Yahoo News· 8 hours agoThe impacted products were distributed to Hy-Vee, Hy-Vee Drugstore and Dollar Fresh Market locations...
New information on ‘Mystery Note’ investigation
PAHomePage.com· 7 hours agoEYEWITNESS NEWS (WBRE/WYOU) — There is new information regarding the investigation into the so-called “Mystery Notes” being found inside sealed food...
These yogurt-covered pretzels might make you sick, FDA warns. Here's what you need to know
LA Times via Yahoo News· 1 day agoProduce & Nuts of Ontario is recalling yogurt-covered pretzels sold at Gelson's Markets and other...
Recall alert: Cream cheese recalled over salmonella concerns
WSB Radio· 8 hours agoThere have been no reports of sickness from the cream cheese.
FDA Orders Recall on Diabetes App After Glitch Injures 224 Users
iTech Post· 2 days agoThe U.S. Food and Drug Administration (FDA) issued a Class I recall t:connect, an iOS app used to...
FDA warns some packaged baby food contains potentially toxic metals
WFTV 9 Orlando· 11 hours agoParents with newborn babies may want to listen to this new warning from the U.S. Food and Drug ...
KORU Medical enters Phase III trial for rare disease therapy By Investing.com
Investing.com· 3 hours agoThis trial follows the successful validation testing of KORU's Freedom System, designed to...
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for...
Benzinga· 1 hour agoTOKYO and CAMBRIDGE, Mass., May 14, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO:
Ascendis Pharma Says FDA Extending Review Period for NDA
Morningstar· 6 hours agoBy Ben Glickman Ascendis Pharma said regulators had pushed back the target action date for reviewing its hypoparathyroidism treatment after the company submitted additional information. The Danish biopharmaceutical company said Tuesday that
